Shopping Cart
Remove All
Your shopping cart is currently empty
Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Backorder | Backorder | |
| 5 mg | Inquiry | Backorder | Backorder |
| Description | Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2]. |
| In vivo | Ormutivimab, at a single dose of 20 IU/kg administered via intramuscular injection, conferred protection to beagles against the lethal challenge of RABV BD06. Similarly, a single intramuscular injection of Ormutivimab, at dosages of 20 IU/kg and 100 IU/kg, provided protective immunity to Kunming mice subjected to various rabies virus strains. |
| Synonyms | rhRIG, NM57 |
| Cas No. | 2449086-91-1 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.